Evidence map›Paper›PMID 22496908›Full record

ArticlePloS one2012

Membrane progesterone receptor alpha as a potential prognostic biomarker for breast cancer survival: a retrospective study.

Mingxuan Xie, Xiangzhu Zhu, Zhaofan Liu, Martha Shrubsole, Vijay Varma, Ingrid A Mayer, Qi Dai, Qiong Chen, Shaojin You

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
1.4field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 35 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 2 countries.

Mingxuan XieHistopathology core, Atlanta Research & Educational Foundation/Atlanta VA Medical Center, Decatur, Georgia, United States of America.
Xiangzhu Zhu
Zhaofan Liu
Martha Shrubsole
Vijay Varma
Ingrid A Mayer
Qi Dai
Qiong Chen
Shaojin You
Atlanta Research and Education Foundation · USVanderbilt University · USAtlanta VA Medical Center · USXiangya Hospital Central South University · CN

Funding

Targeted Therapies in Breast CancerK23CA127469 · NCI · VANDERBILT UNIVERSITY · PI MAYER, INGRID A · 2009 to 2013
$820k
Tumor Peripheral Clocks and Breast Cancer ControlR03CA112645 · NCI · DORN RESEARCH INSTITUTE · PI YOU, SHAOJIN · 2004 to 2005
$104k
NCI NIH HHS K23 CA127469NCI NIH HHS R03 CA112645
6 · The paper itself

Abstract

Classically, the actions of progesterone (P4) are attributed to the binding of nuclear progesterone receptor (PR) and subsequent activation of its downstream target genes. These mechanisms, however, are not applicable to PR- or basal phenotype breast cancer (BPBC) due to lack of PR in these cancers. Recently, the function of membrane progesterone receptor alpha (mPRα) in human BPBC cell lines was studied in our lab. We proposed that the signaling cascades of P4→mPRα pathway may play an essential role in controlling cell proliferation and epithelial mesenchymal transition (EMT) of breast cancer. Using human breast cancer tissue microarrays, we found in this study that the average intensity of mPRα expression, but not percentage of breast cancer with high level of mPRα expression (mPRα-HiEx), was significantly lower in the TNM stage 4 patients compared to those with TNM 1-3 patients; and both average intensities of mPRα expression and mPRα-HiEx rates were significantly higher in cancers negative for ER, as compared with those cancers with ER+. However, after adjusting for age at diagnosis and/or TNM stage, only average intensities of mPRα expression were associated with ER status. In addition, we found that the rates of mPRα-HiEx were significantly higher in cancers with epithelial growth factor receptor-1 (EGFR+) and high level of Ki67 expression, indicating positive correlation between mPRα over expression and EGFR or Ki67. Further analysis indicated that both mPRα-HiEx rate and average intensity of mPRα expression were significantly higher in HER2+ subtype cancers (i.e. HER2+ER-PR-) as compared to ER+ subtype cancers. These data support our hypothesis that P4 modulates the activities of the PI3K and cell proliferation pathways through the caveolar membrane bound growth factor receptors such as mPRα and growth factor receptors. Future large longitudinal studies with larger sample size and survival outcomes are necessary to confirm our findings.

Indexed as

Biomarkers, TumorBreast NeoplasmsCarcinomaErbB ReceptorsFemaleHumansKi-67 AntigenMiddle AgedNeoplasm StagingProgesteronePrognosisReceptors, EstrogenReceptors, ProgesteroneRetrospective StudiesBiomarkers, TumorEGFR protein, humanErbB ReceptorsKi-67 AntigenProgesteroneprogesterone receptor AReceptors, EstrogenReceptors, Progesterone

Identifiers

PMID22496908
PMCPMC3319632
OpenAlexW1968480446

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.